Prospects for development of a vaccine to prevent and control vaginal candidiasis

Current Infectious Disease Reports

Volumn 13, Issue 1, 2011, Pages 102-107

  Fidel Jr , Paul L ^a   Cutler, Jim E ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

Glucan; Animal models; Antibodies; Candida albicans; Conjugate vaccine; Live animal imaging; Mucosal immunity; Vaccine; Vaginal candidiasis; Vaginitis

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIIDIOTYPIC ANTIBODY; ASPARTIC PROTEINASE; BETA GLUCAN; CANDIDA VACCINE; CELL MEMBRANE PROTEIN; CHOLERA TOXIN; DIPHTHERIA TOXOID; FUNGUS VACCINE; GLYCOSYLPHOSPHATIDYLINOSITOL; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2B; LAMINARAN; LIPOSOME; LUCIFERASE; MANNOPROTEIN; MIFAMURTIDE; UNCLASSIFIED DRUG;

ARTICLE; CANDIDA; CANDIDA ALBICANS; DISEASE MODEL; FEMALE; INFECTION CONTROL; MEDICAL LITERATURE; NONHUMAN; PASSIVE IMMUNIZATION; PLATE COUNT; TREATMENT OUTCOME; VAGINA CANDIDIASIS; VAGINAL LAVAGE;

EID: 79551522540     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0143-y     Document Type: Article

References (49)

1. JD Sobel S Faro R Force, et al. 1998 Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations Am J Obstet Gynecol 178 203 211 1:STN:280:DyaK1c7mtVWisw%3D%3D 10.1016/S0002-9378(98)80001-X 9500475 (Pubitemid 28124116)
2. JD Sobel 1988 Pathogenesis and epidemiology of vulvovaginal candidiasis Ann NY Acad Sci 544 547 557 1:STN:280:DyaL1M7gsVaitQ%3D%3D 10.1111/j.1749-6632. 1988.tb40450.x 3063184
3. JD Sobel 1992 Pathogenesis and treatment of recurrent vulvovaginal candidiasis Clin Infect Dis 14 S148 S153 1562688
4. PL Fidel Jr 1996 Sobel JD: Immunopathogenesis of recurrent vulvovaginal candidiasis Clin Microbiol Rev 9 335 348 8809464
5. JE Cutler GS Deepe Jr 2007 Klein BS: Advances in combating fungal diseases: vaccines on the threshold Nat Rev Microbiol 5 13 28 1:CAS:528:DC%2BD28XhtlaktrrP 10.1038/nrmicro1537 17160002 (Pubitemid 44942300)
6. SS Witkin 1986 Inhibition of Candida-induced lymphocyte proliferation by antibody to Candida albicans Obstet Gynecol 68 696 699 1:STN:280: DyaL2s%2FhsFGktg%3D%3D 3531938
7. Hobbs JR, Briden D, Davidson F, et al.: Immunological aspects of candidal vaginitis. Proc R Soc Med 1977, 70:11-14.
8. IW Fong P McCleary S Read 1992 Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis Am J Obstet Gynecol 166 887 890 1:STN:280:DyaK387pslKksA%3D%3D 1550158
9. W Mendling U Koldovsky 1996 Investigations by cell-mediated immunologic tests and therapeutic trials with thymopentin in vaginal mycoses Infect Dis Obstet Gynecol 4 225 231 1:STN:280:DC%2BD1czht1yqsg%3D%3D 10.1002/(SICI)1098- 0997(1996)4:4<225::AID-IDOG5>3.0.CO;2-Y 18476097 (Pubitemid 27114329)
10. PL Fidel Jr ME Lynch V Redondo-Lopez, et al. 1993 Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis (RVVC) J Infect Dis 168 1458 1465 8245529
11. PL Fidel Jr 1994 Lynch ME, Sobel JD: Effects of preinduced Candida -specific systemic cell-mediated immunity on experimental vaginal candidiasis Infect Immun 62 1032 1038 8112837
12. Fidel PL, Jr, Lynch ME, Conaway DH, et al.: Mice immunized by primary vaginal C. albicans infection develop acquired vaginal mucosal immunity. Inf Immun 1995, 63:547-553.
13. RF Hector JE Domer EW Carrow 1982 Immune responses to Candida albicans in genetically distinct mice Infect Immun 38 1020 1028 1:STN:280: DyaL3s7gslGitA%3D%3D 6759403
14. PL Fidel Jr 1995 Lynch ME, Sobel JD: Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis Infect Immun 63 2403 2408 1:CAS:528:DyaK2MXmsF2isro%3D 7790050
15. CA Black FM Eyers ML Dunkley, et al. 1999 Major histocompatibility haplotype does not impact the course of experimentally induced murine vaginal candidiasis Lab Anim Sci 49 668 672 1:CAS:528:DC%2BD3cXntFWhsA%3D%3D 10638507
16. CA Black FM Eyers A Russell, et al. 1999 Increased severity of Candida vaginitis in BALB/c nu/nu mice versus the parent strain is not abrogated by adoptive transfer of T cell enriched lymphocytes J Reprod Immunol 45 1 18 1:STN:280:DC%2BD3c7itlKmtw%3D%3D 10.1016/S0165-0378(99)00017-0 10660259 (Pubitemid 29486727)
17. U Nawrot K Grzybek-Hryncewicz U Zielska, et al. 2000 The study of cell-mediated immune response in recurrent vulvovaginal candidiasis [In Process Citation] FEMS Immunol Med Microbiol 29 89 94 1:CAS:528:DC%2BD3cXmvFyrtro%3D 10.1111/j.1574-695X.2000.tb01509.x 11024346
18. EM Corrigan RL Clancy ML Dunkley, et al. 1998 Cellular immunity in recurrent vulvovaginal candidiasis Clin Exp Immunol 111 574 578 1:STN:280:DyaK1c7oslOmsg%3D%3D 10.1046/j.1365-2249.1998.00525.x 9528901 (Pubitemid 28160903)
19. PL Fidel Jr W Luo C Steele, et al. 1999 Analysis of vaginal cell populations during experimental vaginal candidiasis Infect Immun 67 3135 3140 1:CAS:528:DyaK1MXjsFSnsbo%3D 10338532 (Pubitemid 29244741)
20. BN Taylor M Saavedra PL Fidel Jr 2000 Local Th1/Th2 cytokine production during experimental vaginal candidiasis Med Mycol 38 419 431 1:CAS:528:DC%2BD3MXhtFKgtL0%3D 11204879
21. PR Dunbar J Hill TJ Neale, et al. 1992 Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia Psycho Med 22 1051 1057 1:STN:280:DyaK3s7ktFKruw%3D%3D 10.1017/S0033291700038629
22. E Cenci A Mencacci R Spaccapelo, et al. 1995 T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development J Infect Dis 171 1279 1288 1:CAS:528:DyaK2MXmtF2gsrs%3D 7751704
23. PL Fidel Jr M Barousse T Espinosa, et al. 2004 A live intravaginal Candida challenge in humans reveals new hypotheses for the immunopathogenesis of vulvovaginal candidiasis Infect Immun 72 2939 2946 10.1128/IAI.72.5.2939-2946. 2004 15102806 (Pubitemid 38542424)
24. • Yano J, Lilly E, Barousse M, et al.: Epithelial cell-derived S100 calcium-binding proteins as key mediators in the hallmark acute neutrophil response during Candida vaginitis. Infect Immun 2010, in press. This article describes the novel discovery of the role of calcium-binding proteins in the acute inflammatory response by neutrophils during Candida vaginitis.
25. FL Wormley Jr C Steele K Wozniak, et al. 2001 Resistance of TCR δ-chain knock-out mice to experimental Candida vaginitis Infect Immun 69 7162 7164 1:CAS:528:DC%2BD3MXnvFWjtrk%3D 10.1128/IAI.69.11.7162-7164.2001 11598094 (Pubitemid 32995479)
26. DM LeBlanc MM Barousse PL Fidel Jr 2006 A role for dendritic cells in immunoregulation during experimental vaginal candidiasis Infect Immun 74 3213 3221 1:CAS:528:DC%2BD28Xlt1Cgtb8%3D 10.1128/IAI.01824-05 16714548 (Pubitemid 43794509)
27. G Santoni M Boccanera D Adriani, et al. 2002 Immune cell-mediated protection against vaginal candidiasis: Evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors Infect Immun 70 4791 4797 1:CAS:528:DC%2BD38Xmtl2itbo%3D 10.1128/IAI.70.9.4791- 4797.2002 12183521
28. F De Bernardis G Santoni M Boccanera, et al. 2010 Protection against rat vaginal candidiasis by adoptive transfer of vaginal B lymphocytes FEMS Yeast Res 10 432 440 10.1111/j.1567-1364.2010.00620.x 20402794
29. A Cassone M Boccanera DA Adriani, et al. 1995 Rats clearing a vaginal infection by Candida albicans aquire specific, antibody-mediated resistance to vaginal infection Infect Immun 63 2619 2624 1:CAS:528:DyaK2MXmsF2isbo%3D 7790077
30. F De Bernardis M Boccanera D Adriana, et al. 1997 Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats Infect Immun 65 3399 3405 9234804
31. S Mathur G Virella J Koistinen, et al. 1977 Humoral immunity in vaginal candidiasis Infect Immun 15 287 294 1:STN:280:DyaE2s%2FptlSisg%3D%3D 319061
32. KL Wozniak FL Wormley Jr PL Fidel Jr 2002 Candida-specific antibodies during experimental vaginal candidiasis in mice Infect Immun 70 5790 5799 1:CAS:528:DC%2BD38XnsV2ltrc%3D 10.1128/IAI.70.10.5790-5799.2002 12228309
33. Y Han RP Morrison JE Cutler 1998 A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection Infect Immun 66 5771 5776 1:CAS:528:DyaK1cXnvVChur8%3D 9826353
34. F De Bernardis M Boccanera D Adriani, et al. 2002 Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis Infect Immun 70 2725 2729 10.1128/IAI.70.5.2725-2729.2002 11953420 (Pubitemid 34408424)
35. Y Han MH Riesselman JE Cutler 2000 Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody Infect Immun 68 1649 1654 1:CAS:528: DC%2BD3cXhsVKrtr4%3D 10.1128/IAI.68.3.1649-1654.2000 10678984 (Pubitemid 30108568)
36. Y Han TR Kozel MX Zhang, et al. 2001 Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis J Immunol 167 1550 1557 1:CAS:528:DC%2BD3MXls1Wrs7o%3D 11466376
37. D Rahman M Mistry S Thavaraj, et al. 2007 Murine model of concurrent oral and vaginal Candida albicans colonization to study epithelial host-pathogen interactions Microbes Infect 9 615 622 1:CAS:528:DC%2BD2sXksVyit7k%3D 10.1016/j.micinf.2007.01.012 17383212 (Pubitemid 46602022)
38. L Polonelli F De Bernardis S Conti, et al. 1994 Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies J Immunol 152 3175 3182 1:CAS:528:DyaK2cXis1OltLo%3D 8144911
39. BJ Spellberg AS Ibrahim V Avanesian, et al. 2006 Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis J Infect Dis 194 256 260 1:CAS:528:DC%2BD28XnsFSrsro%3D 10.1086/504691 16779733 (Pubitemid 44087198)
40. M Raska J Belakova M Horynova, et al. 2008 Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis Med Mycol 46 411 420 1:CAS:528:DC%2BD1cXos1Wqtb4%3D 10.1080/13693780701883508 18608941 This article describes partial protection against vaginitis following immunization with C. albicans heat shock protein 90
41. A Torosantucci C Bromuro P Chiani, et al. 2005 A novel glyco-conjugate vaccine against fungal pathogens J Exp Med 202 597 606 1:CAS:528: DC%2BD2MXhtVSjs7zN 10.1084/jem.20050749 16147975 (Pubitemid 41258184)
42. MD Moragues MJ Omaetxebarria N Elguezabal, et al. 2003 A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities Infect Immun 71 5273 5279 1:CAS:528: DC%2BD3sXntFOqtrw%3D 10.1128/IAI.71.9.5273-5279.2003 12933874 (Pubitemid 37070774)
43. D Pietrella A Rachini A Torosantucci, et al. 2010 A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique Vaccine 28 1717 1725 1:CAS:528:DC%2BC3cXhs1Gqsrc%3D 10.1016/j.vaccine.2009.12.021 20038431 This article describes partial protection against vaginitis in mice vaccinated with β-glucan conjugate vaccine and evaluated by a novel live animal imaging technique.
44. E Moreno-Ruiz G Ortu PW de Groot, et al. 2009 The GPI-modified proteins Pga59 and Pga62 of Candida albicans are required for cell wall integrity Microbiol 155 2004 2020 1:CAS:528:DC%2BD1MXnvFGmur0%3D 10.1099/mic.0.028902-0
45. B Enjalbert A Rachini G Vediyappan, et al. 2009 A multifunctional, synthetic Caussia princeps luciferase reporter for live imaging of Candida albicans infections Infect Immun 77 4847 4858 1:CAS:528:DC%2BD1MXhtl2itrjO 10.1128/IAI.00223-09 19687206
46. A Torosantucci P Chiani C Bromuro, et al. 2009 Protection by anti-beta-glucan antibodies is associated with restricted beta-1, 3 glucan binding specificity and inhibition of fungal growth and adherence PLoS ONE 4 e5392 10.1371/journal.pone.0005392 19399183 The mechanism of protection by anti-β-glucan antibodies is uncovered
47. A Casadevall MD Scharff 1994 Serum therapy revisited: animal models of infection and development of passive antibody therapy Antimicrob Agents Chemother 38 1695 1702 1:STN:280:DyaK2M%2Fnsleiuw%3D%3D 7985997
48. A Mencacci A Torosantucci R Spaccapelo, et al. 1994 A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice Infect Immun 62 5353 5360 1:CAS:528:DyaK2MXitlShtrs%3D 7960114
49. B Spellberg AS Ibrahim L Lin, et al. 2008 Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity J Infect Dis 197 967 971 1:CAS:528:DC%2BD1cXkvFOhtLo%3D 10.1086/529204 18419471 Partial protection against vaginitis is shown with ALS3 vaccine candidate (Pubitemid 351590024)